Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 7, 2016, Pages 1177-1191

  Bjerke, Maria ^a   Andreasson, Ulf ^a   Kuhlmann, Julia ^b   Portelius, Erik ^a   Pannee, Josef ^a   Lewczuk, Piotr ^c,m   Umek, Robert M ^d   Vanmechelen, Eugeen ^e   Vanderstichele, Hugo ^e   Stoops, Erik ^e   Lewis, Jennifer ^d   Vandijck, Manu ^f   Kostanjevecki, Vesna ^f   Jeromin, Andreas ^g   Salamone, Salvatore J ^h   Schmidt, Oliver ⁱ   Matzen, Anja ⁱ   Madin, Kairat ^j   Eichenlaub, Udo ^j   Bittner, Tobias ^j   Shaw, Leslie M ^k   Zegers, Ingrid ^b   Zetterberg, Henrik ^a,l   Blennow, Kaj ^a   more..

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b JOINT RESEARCH CENTRE   (Italy)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Meso Scale Discovery ^*  (United States)

^e ADX NEUROSCIENCES   (Belgium)

^f FUJIREBIO INC   (Japan)

^g QUANTERIX CORPORATION   (United States)

^h SALADAX BIOMEDICAL INC   (United States)

ⁱ IBL International GmbH   (Germany)

^j ROCHE DIAGNOSTICS GMBH   (Germany)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

more..

Author keywords

Alzheimer's disease; amyloid; biomarker; cerebrospinal fluid; commutability; reference material

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

AMINO ACID ANALYSIS; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; STANDARD; STANDARDS; TANDEM MASS SPECTROMETRY;

AMYLOID BETA-PEPTIDES; BIOMARKERS; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84974691647     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0733     Document Type: Article

References (33)

1. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
2. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
3. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-6.
4. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
5. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74:826-36.
6. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against amyloid positron emission tomography. J Am Med Assoc Neurol 2014;71:1282-9.
7. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-9.
8. Duits FH, Prins ND, Lemstra AW, Pijnenburg YA, Bouwman FH, Teunissen CE, et al. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimers Dement 2015;11:523-32.
9. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 2014;13:614-29.
10. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
11. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
12. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
13. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 2006;409:1-4.
14. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009;46(Pt 3):235-40.
15. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011;7:386-95. e6.
16. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-61.
17. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-45.
18. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), tau, and phosphorylated tau in Alzheimer's disease: Report of an International Workshop. Int J Alzheimers Disease 2010;2010. pii: 635053.
19. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Disease 2010;2010. pii: 986310.
20. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65-73.
21. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 2012;6:419-30.
22. Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. J Neurosci Meth 2010;193:296-9.
23. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs S, De Deyn P, Shaw L, et al. Alzheimer's disease biomarkers: from concept to clinical utility In: Galimberti D, Scarpini E, editors. BioMarkers for early diagnosis of Alzheimer's disease. Nova Science Publishers, Inc., 2008:81-122.
24. Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H. Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark Med 2012;6:377-89.
25. Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, et al. Alzheimer disease biomarker testing in cerebrospinal fluid: A method to harmonize assay platforms in the absence of an absolute reference standard. Clin Chem 2013;59:710-2.
26. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis 2013;33:1021-32.
27. Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin Chem 2014;60:987-94.
28. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-20.
29. R Core Team. A language and environment for statistical computing. 2013, R Foundation for Statistical Computing: Vienna, Austria. URL http://www. R-project. org/.
30. Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42. Biomark Med 2012;6:409-17.
31. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement 2013;9:137-40.
32. Zegers I, Beetham R, Keller T, Sheldon J, Bullock D, MacKenzie F, et al. The importance of commutability of reference materials used as calibrators: The example of ceruloplasmin. Clin Chem 2013;59:1322-9.
33. Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis 2014;41:441-51.